Tat-NTS peptide
Based on 1 Customer Validation
Tat-NTS peptide is a cell-penetrating peptide with neuroprotective effects. Tat-NTS peptide can specifically inhibit the nuclear translocation of ANXA1 and reduce neuronal apoptosis in ischemic areas. Moreover, Tat-NTS peptide can reduce the volume of cerebral ischemic infarction and can be used in the research of ischemic stroke.
For research use only. We do not sell to patients.
- Purity: 99.88%
- Formula: C125H212N54O24
- Molecular Weight:2855.37
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Tat-NTS peptide (20 μM) blocks ANXA1 nuclear migration in neuronal cells without affecting the nuclear translocation of other proteins[1].
Tat-NTS peptide (20 μM) inhibits the binding of ANXA1 to p53, alleviates neuronal apoptosis induced by oxygen glucose deprivation/reperfusion (OGD/R), and has neuronal cytoprotective effects[1].
Tat-NTS peptide (20 μM) can significantly improve the viability of neuronal cells after OGD/R[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:neuronal cells
-
Concentration:20 μM
-
Incubation Time:
-
Result:Significantly decreased the level of ANXA1 protein in the nuclear fraction, and had no impact on the subcellular localization of p65 and β-catenin.
Significantly decreased Bid protein levels.
Significantly decreased OGD/R-triggered tBid expression and caspase-9, PARP, caspase-3 cleavage but had little effect on the activation of caspase-8.
-
Cell Line:neuronal cells
-
Concentration:20 μM
-
Incubation Time:
-
Result:Significantly decreased Bid mRNA levels.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:MCAO C57BL/6 mice model[1]
-
Dosage:0.5 mg/kg, 1 mg/kg, 2 mg/kg, 5 mg/kg, 10 mg/kg.
-
Administration:Unilateral Intracerebroventricular (i.c.v.) Injection: Single dose. After undergoing 1-hour middle cerebral artery occlusion (MCAO)
-
Result:Significantly inhibited the protein level of tBid, cleaved caspase-9, cleaved PARP, and caspase-3, and had little effect on the activation of caspase-8.
Reduced the infarct volume and improved neurological outcomes following focal ischemic injury.
Chemical Information
-
Appearance Solid
-
Molecular Weight 2855.37
-
Formula C125H212N54O24
-
Color White to off-white
-
Sequence
Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Arg-Ser-Phe-Pro-His-Leu-Arg-Arg-Val-Phe-NH2
-
Sequence Shortening
YGRKKRRQRRRRSFPHLRRVF-NH2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
H2O : ≥ 100 mg/mL (35.02 mM)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 0.3502 mL | 1.7511 mL | 3.5022 mL | 8.7554 mL |
| 5 mM | 0.0700 mL | 0.3502 mL | 0.7004 mL | 1.7511 mL | |
| 10 mM | 0.0350 mL | 0.1751 mL | 0.3502 mL | 0.8755 mL | |
| 15 mM | 0.0233 mL | 0.1167 mL | 0.2335 mL | 0.5837 mL | |
| 20 mM | 0.0175 mL | 0.0876 mL | 0.1751 mL | 0.4378 mL | |
| 25 mM | 0.0140 mL | 0.0700 mL | 0.1401 mL | 0.3502 mL | |
| 30 mM | 0.0117 mL | 0.0584 mL | 0.1167 mL | 0.2918 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Tat-NTS peptide Related Classifications
HY-P10275 Related Classifications
Powered by Bioz